Articles

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie

Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, AKH Linz, Austria;Departments of Internal Medicine I, Divisions of Oncology and the Comprehensive Cancer Center, AKH Linz, Austria
Departments of Internal Medicine I, Divisions of Oncology and the Comprehensive Cancer Center, AKH Linz, Austria
Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, AKH Linz, Austria
Department of Internal Medicine V, Hematology and Oncology, Medical University of Innsbruck, AKH Linz, Austria
Department of Internal Medicine, Division of Hematology, Medical University of Graz, AKH Linz, Austria
Department of Internal Medicine, Division of Hematology, Medical University of Graz, AKH Linz, Austria
Department of Internal Medicine, Divison of Oncology, AKH Linz, Austria
Departments of Pathology of the Medical University of Vienna, AKH Linz, Austria
Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, AKH Linz, Austria
Departments of Internal Medicine I, Divisions of Oncology and the Comprehensive Cancer Center, AKH Linz, Austria
Vol. 98 No. 2 (2013): February, 2013 https://doi.org/10.3324/haematol.2012.072587